ANAPTYSBIO, INC — Director's Dealing 2017

Jan 26, 2017

SEC Form 3 — Initial Statement of Beneficial Ownership

Issuer: ANAPTYSBIO INC (ANAB)
CIK: 0001370053
Period of Report: 2017-01-25

Reporting Person: Londei Marco (Chief Medical Officer)

Holdings (Derivative)

Security	Exercise Price	Expiration	Underlying	Shares	Ownership
Series D Preferred Stock	$0.00		Common Stock (2020)		Direct
Employee Stock Option (right to buy)	$0.70	2024-10-27	Common Stock (160965)		Direct
Employee Stock Option (right to buy)	$6.93	2025-08-13	Common Stock (92223)		Direct

Footnotes

F1: Each share of Preferred Stock will be automatically converted into one (1) share of Common Stock, for no additional consideration, immediately prior to the consummation of the Issuer's initial public offering, and has no expiration date.

F2: The stock option vested and became exercisable as to 25% of the shares subject to the option on October 24, 2015, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.

F3: The stock option vested and became exercisable as to 25% of the shares subject to the option on August 13, 2016, and thereafter vests as to 1/48th of the shares in equal monthly installments, until such time as the option is 100% vested, subject to the continuing employment of the Reporting Person on each vesting date.